K-ras genotypes and prognosis in non-small-cell lung cancer

R. Rosell, M. Monzo, F. Molina, E. Martinez, A. Pifarre, I. Moreno, J. L. Mate, J. M. De Anta, M. Sanchez, A. Font

Producción científica: Contribución a una revistaArtículo en revista científica indexadarevisión exhaustiva

27 Citas (Scopus)

Resumen

Background: Despite major advances in the treatment of many kinds of cancer over the past 25 years, the overall 5-year survival of non-small-cell lung cancer patients has scarcely improved. Even in stage I which has the best outcome long-term survival still falls below 70%. Since intriguing data suggest that the identification of genetic markers might allow prognosis to be assessed case by case. We were prompted to evaluate K-ras gene mutations as a putative prognostic marker in this neoplasm. Materials and methods: We used the polymerase chain reaction (PCR) followed by allele specific oligonucleotide (ASO) hybridization or single-strand conformation polymorphism (SSCP) assays, to detect K-ras mutations in DNA from formalin-fixed, paraffin-embedded tumor samples. K-ras mutations were examined in 192 stage I to IV non-small-cell lung cancer patients. Results: K-ras mutations were detected in 51 of 192 of the cases studied (27%). All K-ras mutations detected by PCR/ ASO hybridization were also identified by SSCP. In stage I disease, the median survival time was 46 months in those patients whose tumors had no K-ras mutations and 21 months in those with aspartic acid and serine mutations at K-ras codon 12; in patients with stage IIIA disease, median survival time was 16 months in the K-ras negative group and 7 months in the aspartic acid and serine mutation group. No significant differences were observed for the remaining amino acid substitutions of K-ras, nor were they observed at all in more advanced disease. Conclusions: K-ras gene status has strong prognostic value in patients with stage IIIA non-small-cell lung cancer. The survival curve for patients with stage I and K-ras codon 12 aspartic or serine mutations is close to that of patients with stage IIIA without K-ras mutations. However, a non-small-cell lung cancer K-ras genotypic classification should be validated in larger studies.

Idioma originalInglés
Páginas (desde-hasta)15-20
Número de páginas6
PublicaciónAnnals of Oncology
Volumen6
N.ºSUPPL. 3
DOI
EstadoPublicada - 1995
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'K-ras genotypes and prognosis in non-small-cell lung cancer'. En conjunto forman una huella única.

Citar esto